Objective-To establish the cellular source of plasma factor (F)XIII-A. Approach and Results-A novel mouse floxed for the F13a1 gene, FXIII-A flox/flox (Flox), was crossed with myeloid-and platelet-cre-expressing mice, and cellular FXIII-A mRNA expression and plasma and platelet FXIII-A levels were measured. The platelet factor 4-cre.Flox cross abolished platelet FXIII-A and reduced plasma FXIII-A to 23±3% (P<0.001). However, the effect of platelet factor 4-cre on plasma FXIII-A was exerted outside of the megakaryocyte lineage because plasma FXIII-A was not reduced in the Mpl −/− mouse, despite marked thrombocytopenia. In support of this, platelet factor 4-cre depleted FXIII-A mRNA in brain, aorta, and heart of floxed mice, where FXIII-A pos cells were identified as macrophages as they costained with CD163. In the integrin αM-cre.Flox and the double copy lysozyme 2-cre.cre.Flox crosses, plasma FXIII-A was reduced to, respectively, 75±5% (P=0.003) and 30±7% (P<0.001), with no change in FXIII-A content per platelet, further consistent with a macrophage origin of plasma FXIII-A. The change in plasma FXIII-A levels across the various mouse genotypes mirrored the change in FXIII-A mRNA expression in aorta. Bone marrow transplantation of FXIII-A +/+ bone marrow into FXIII-A −/− mice both restored plasma FXIII-A to normal levels and replaced aortic and cardiac FXIII-A mRNA, while its transplantation into FXIII-A +/+ mice did not increase plasma FXIII-A levels, suggesting that a limited population of niches exists that support FXIII-A-releasing cells. 
; therefore, the cell type that releases FXIII-A into the plasma must be reasonably numerous. In mammals, FXIII-A is expressed in megakaryocytes, monocytes, osteocytes, chondrocytes, dendritic cells, and bone marrow (BM)-derived macrophages, which have polarized to the M2 phenotype.
2 FXIII-A is expressed in resident macrophages in organs, including heart, aorta, skin, and placenta, [3] [4] [5] but not in liver, spleen, and kidney. 6 FXIII-A lacks a classical signal peptide, 7 and its mechanism of release remains uncharacterized. As a consequence, plasma FXIII-A may not be released from every cell type in which it is expressed. The outcomes of human BM transplant (BMT) studies have variously implicated platelets, macrophages, and unidentified extra-hematopoietic cells as possible sources of plasma FXIII-A. [8] [9] [10] [11] Our previous studies suggested that the platelet is not the source of plasma FXIII-A because in 2 severely thrombocytopenic mouse lines, BCl x Plt20/Plt20
and Mpl −/− , plasma FXIII-A levels were normal. 3 However, a possibility that we did not fully address is that thrombocytopenia per se might induce upregulation of platelet proteins, including FXIII-A, either within the megakaryocyte lineage or within a rescuing cell type. Therefore, in the current study, we have measured FXIII-A in platelets from the Mpl −/− mouse and have investigated the source of plasma FXIII-A by crossing a novel FXIII-A floxed mouse with mice that individually express platelet factor (Pf)4-cre, integrin αM (CD11b)-cre, or lysozyme 2 (LysM)-cre. CD11b is highly expressed on monocytes, inflammatory macrophages, and osteoclasts and is low or absent in certain populations of yolk sac (YS)-derived macrophages, 12, 13 while LysM is expressed on numerous macrophage subpopulations.
14 The Pf4-cre was designed to delete in the platelet lineage, 15 but a recent reporter mouse study has also shown Pf4-cre expression within resident macrophages. 16 In this study, we relate the extent of plasma FXIII-A depletion to the loss of FXIII-A mRNA levels in our cre/lox crosses and deduce that a macrophage population maintains plasma FXIII-A.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Plasma FXIII-A Levels Are Consistent With Either a Platelet or a Myeloid Origin in cre/lox FXIII-A-Deficient Mice
The presence of the flippase recombinase target or LoxP sites within the F13a1 gene of the floxed mouse ( Figure I in the online-only Data Supplement) slightly decreased plasma FXIII-A activity to 85±5% of C57BL/6 wild-type (WT) mice ( Figure 1A) . Consequently, results are presented either relative to WT mice ( Figure 1A ) or, where more appropriate, relative to FXIII-A.Flox mice ( Figure 1B) . Plasma FXIII-A activity was absent in the novel FXIII-A −/− mouse, while plasma FXIII-A activity in heterozygous mice was 61±3% (P<0.001; Figure 1A ), in agreement with previously described FXIII-A +/− mice. 17 FXIII-A activity measurements were corroborated by immunoblotting, with generally good agreement between methods (Figure 1) . FXIII-A.Flox mice were crossed with mice expressing cre recombinase in megakaryocytes and certain macrophage populations (Pf4-cre 15, 16 ) or exclusively in myeloid cells (LysMcre 14 and CD11b-cre 13 ). In Pf4-cre.Flox mice, plasma FXIII-A activity was reduced to 23±3% (P<0.001; Figure 1B ). To determine whether the residual 23% was explained by suboptimal Pf4-cre expression, we bred mice harboring 2 copies of this transgene, using quantitative polymerase chain reaction of genomic (g)DNA to assess copy number (1 copy normalized to 1.00±0.038, n=12 and 2 copy to 1.83±0.060, n=6).
Pf4-cre.cre.Flox mice did not show a statistically significant further decrease in plasma FXIII-A activity (17±1%, P=0.48; Figure 1B ), suggesting that incomplete depletion is not explained by suboptimal expression of Pf4-cre.
In CD11b-cre.Flox and LysM-cre.Flox mice, plasma FXIII-A was reduced to 75±5% (P=0.003; Figure 1B ) and 57±5% (P<0.001; Figure 1B ), respectively. The LysM-cre knock-in undergoes silencing, 18 and possibly on account of this, we observed a significant further reduction in plasma FXIII-A (to 30±7%) in 2-copy LysM-cre.cre.Flox mice relative to LysM-cre.Flox mice (P<0.001; Figure 1B ). The sum of the plasma FXIII-A reductions achieved individually with Pf4-cre.Flox (77%) and either CD11b-cre.Flox (25%) or LysM-cre.cre.Flox (70%), respectively, equals or exceeds 100%. In contrast, while dual-expressing CD11b-cre.Pf4-cre.Flox mice showed a further reduction in plasma FXIII-A activity (11±2%; Figure 1B ) over the Pf4-cre.Flox mice (P<0.001), plasma FXIII-A was not completely eliminated. These results suggest that the plasma FXIII-A-releasing cell expresses both Pf4 and myeloid markers. interpreted as indicating that the megakaryocyte-platelet lineage makes a significant contribution to plasma FXIII-A. To further exclude the platelet lineage as the major source of plasma FXIII-A, we demonstrated that Mpl −/− mice have normal plasma FXIII-A activity (95±4%, P=0.49; Figure 1A ), despite platelet counts in whole blood being 6.4±5% of WT (P<0.0001). In contrast, platelet counts did not differ between WT mice and the various cre/lox mice ( Figure 2A ). We established that the size distribution of Mpl −/− platelets was equivalent to that of WT ( Figure 2B ) and that FXIII-A activity and protein per platelet were normal (92±6%; Figure 2C ). In addition, because thrombocytopenia has been suggested to induce hepatic FXIII-A expression, 9 we determined by reverse transcriptase polymerase chain reaction that hepatic FXIII-A mRNA was undetectable in either the Mpl −/− or WT mice (C t >40). Together, these results both exclude compensatory FXIII-A upregulation in platelets or hepatic cells as a mechanism whereby plasma FXIII-A is maintained and further discount the platelet as the source of plasma FXIII-A.
In the platelet, FXIII-A activity was abolished in Pf4-cre. Flox mice ( Figure 2D) , showing that single-copy Pf4-cre mice underwent efficient deletion. Moreover, platelet FXIII-A was unaffected in the CD11b-cre.Flox (83±10%), LysM-cre.Flox (111±3%), and LysM-cre.cre.Flox (94±10%) mice ( Figure 2D ), Figure 3 . A, Genomic F13a1 recombination in the tissues indicated was determined in Pf4-cre.Flox (dark bars) and CD11b-cre.Flox (white bars) mice. Results are expressed as mean±SEM (n≥3). B and C, Immunofluorescent staining detects factor (F)XIII-A (red) cells in wildtype (WT) but not FXIII-A −/− heart sections. Nuclei are shown in blue. B, A proportion of FXIII-A-labeled cells adopt a spindle-shaped morphology characteristic of cardiac macrophages (inset). Scale bar represents 50 μm. C, Some of these FXIII-A pos cells costain for CD163 (green). Scale bar is 5 μm. D-F, mRNA was isolated from indicated tissues and cDNA subjected to quantitative polymerase chain reaction (qPCR) using housekeeping (HK) transcripts ribosomal protein L32 and β-actin. All results are displayed as mean with 95% confidence interval (CI). D, FXIII-A mRNA expression was measured in heart (light yellow bars) and aorta (dark yellow bars) in mice of the genotypes indicated. Numbers of separate mouse samples are shown in parentheses. E, Endogenous Pf4 transcripts (light pink bars) in WT aorta and heart (n=4) were measured by reverse transcriptase (RT)-PCR, and reaction products were resolved on agarose gels (inset). Transcript levels were enriched in WT-cultured BM-derived macrophages (BMDM, n=4) at levels similar to endogenous CD11b transcripts (dark pink bars), as well as in a FXIII-A-enriched cardiac cell fraction (FEF, n=4). F, FXIII-A mRNA expression was measured in brains (n=3) of young mice of the genotypes indicated. CD11b indicates integrin αM; Flox, FXIII-Aflox/flox; LysM, lysozyme 2; and Pf4, platelet factor 4.
A D F E C B
confirming that these myeloid-cre mice exert their effects on plasma FXIII-A through the myeloid rather than the megakaryocyte lineage. Together, these results suggest that Pf4-cre depletes plasma FXIII-A by acting within myeloid cells, and that these cells are the major site from which plasma FXIII-A is released.
FXIII-A pos Cardiac Cells Are Pf4-Expressing Macrophages
We assayed the extent of F13a1 genomic deletion using quantitative polymerase chain reaction of gDNA, with reference to a standard curve ( Figure II in the online-only Data Supplement). Genomic F13a1 recombination was essentially as previously described in the organs of CD11b-cre. Flox mice. 13 In Pf4-cre.Flox mice, genomic deletion totaled 3.5% in heart and 3.4% in aorta and was lower in other organs examined ( Figure 3A) , excluding the possibility that Pf4-cre expression was promiscuous in Pf4-cre.Flox mice.
We examined the expression of FXIII-A mRNA in heart and aorta, where functional roles of FXIII-A have been described. 19, 20 Immunofluorescence studies revealed FXIII-A pos cells in WT, but not knockout heart ( Figure 3B ). Some of these FXIII-A pos cells appeared as spindles (inset Figure 3B ), in agreement with their previous identification as macrophages. 21 Moreover, coimmunofluorescence for CD163 and FXIII-A ( Figure 3C ) and immunohistochemistry of consecutive WT heart sections ( Figure III in the online-only Data Supplement) confirmed that ≈80% of the FXIII-A pos cells are CD163 pos macrophages (Table 1) . FXIII-A mRNA was abolished in heart and depleted in aorta in Pf4cre.Flox mice ( Figure 3D ). The complete depletion of FXIII-A mRNA in the heart is broadly consistent with the extent of gDNA recombination (3.5%) and the frequency of FXIII-A pos cells (5%; Table 1 ), provided that Pf4-cre expression is restricted to FXIII-A pos cells. Importantly, in LysM-cre.cre.Flox mice, FXIII-A mRNA was substantially depleted from these tissues, while it was conserved in the Mpl −/− mouse, confirming that FXIII-A pos cells are myeloid rather than platelet/megakaryocyte in origin. As expected, the proportional deletion of the FXIII-A mRNA reflected the loss of FXIII-A pos cells across the various genotypes (Table 1) . Authentic Pf4 transcripts were detected in WT hearts and aorta (insert, Figure 3E ), as well as in Mpl −/− hearts (data not shown). Pf4 transcripts were 40-fold enriched in cultured BM-derived macrophages over whole hearts, while the ratio of Pf4 mRNA to CD11b mRNA was comparable between BM-derived macrophages and whole heart ( Figure 3E ). This is consistent with Pf4 and CD11b mRNA being present at a similar concentration within cardiac macrophages, which represent a minor proportion of the tissue.
Finally, we analyzed cell fractions from collagenase-digested hearts obtained with the Miltenyi neonatal cardiac fibroblast isolation kit. In a fraction that was ≈8-fold enriched in FXIII-A mRNA (FEF) and which represented ≈3% of total heart cell mass, Pf4 and CD11b mRNA were, respectively, 20-fold and 14-fold enriched ( Figure 3E ). Together, these data indicate that the FXIII-A pos cardiac cells are Pf4-expressing macrophages.
Plasma FXIII-A Originates From Cells Resembling Aortic Macrophages
In the brain, where because of the blood-brain barrier, macrophages derive exclusively from primitive YS hematopoiesis, 22, 23 we observed that FXIII-A pos cells are present at similar levels The values show the total amount of cells counted, as well as those positive for FXIII-A and CD163. The percentage of total FXIII-A pos cells was as expected from the FXIII-A mRNA levels shown in Figure 3D . A high proportion of FXIII-A pos cells costained for CD163, suggesting that they are macrophages. CD11b indicates integrin αM; Flox, FXIII-Aflox/flox; KO, knockout; LysM, lysozyme 2; and Pf4, platelet factor 4. in WT and Mpl −/− mice ( Figure 3F ). This shows that, as in heart and aorta, the FXIII-A pos cells in the brain do not arise from the platelet lineage. Moreover, FXIII-A mRNA was depleted from the brain of the Pf4-cre.Flox mouse ( Figure 3F ), suggesting that YS-derived macrophages, as BM-derived macrophages, coexpress Pf4 and FXIII-A. Table 2 shows that the Pf4-cre-mediated reduction in cardiac FXIII-A mRNA (to <1%) greatly exceeds the depletion of the plasma FXIII-A (to ≈20%), making it unlikely that the majority of cardiac cells contribute to the plasma FXIII-A pool. However, in aorta, we observed a similar profile of depletion of FXIII-A mRNA (to ≈14%) to plasma FXIII-A. We, therefore, conclude that plasma FXIII-A is released from cells, similar or identical to those present in the aorta, and that these cells resemble YS-derived macrophages. , consistent with engraftment of donor macrophages ( Figure 4B ). FXIII-A mRNA expression was detectable in hearts, aortas, and brains of the recipient FXIII-A −/− mice ( Figure 4C ), the expression in brain being the consequence of irradiation breaching the blood-brain barrier. 22, 23 There was no increase in plasma FXIII-A or FXIII-A mRNA after BMT into WT recipients, suggesting that there are a limited number of niches that become occupied by FXIII-A-expressing cells.
BMT Repopulates Resident Macrophages in Heart and Aorta and Reconstitutes Plasma FXIII-A in FXIII-
Discussion
Previously, we demonstrated that plasma FXIII-A levels are normal in the thrombocytopenic Mpl −/− and BCl x Plt20/Plt20 mice. 3 However, we did not assay platelet FXIII-A in the Mpl −/− mouse, in which depletion of ≈94% platelets and their precursors results from knockout of the thrombopoietin receptor. 24 Here, we have shown that the amount of FXIII-A per platelet has not increased to compensate for thrombocytopenia. Platelets arise from fragmentation of megakaryocytes 25 ; therefore, cytosolic FXIII-A concentrations in megakaryocytes from the Mpl −/− mouse should also be unchanged. This makes it improbable for platelets and megakaryocytes to be major contributors to the plasma FXIII-A pool, although we cannot exclude a minor contribution.
We next compared the effects of recombination by lineagespecific cre mice on plasma FXIII-A and cellular FXIII-A mRNA levels. Plasma FXIII-A, but not platelet FXIII-A, was partially depleted in CD11b-cre.Flox and LysM-cre.cre.Flox mice, suggesting that macrophages maintain plasma FXIII-A and further excluding the megakaryocyte lineage as a major contributor.
In Pf4-cre.Flox mice, platelet FXIII-A was abolished, while plasma FXIII-A was reduced to 23%. This result further supports a macrophage origin for FXIII-A because a stop/flox study has established that Pf4-cre expression occurs within resident tissue macrophages in addition to megakaryocytes. 16 Notably, Pf4-cre-mediated recombination within macrophages is mosaic, 16 potentially accounting for incomplete depletion of plasma FXIII-A. The FXIII-Aexpressing cells in brain, heart, and aorta have been previously identified as macrophages, 19, 20 and consistent with this, we show (1) that in heart, as previously demonstrated in skin, 26 FXIII-A partially co-localizes with the M2 macrophage marker CD163 and (2) that in heart, brain, and aorta, Pf4-cre depleted FXIII-A mRNA. The expression of Pf4-cre within resident macrophages is likely to be faithful because expression of Pf4 protein was previously demonstrated in adherent cultures of human monocytes 27, 28 and confirmed by us in mouse BM-derived macrophages. In whole heart, as well as in a FXIII-A-enriched cardiac cell fraction, we demonstrated that the ratio of Pf4 to CD11b transcripts was similar to that in BM-derived macrophages, as expected if the Pf4 pos cells in the heart are macrophages.
The profile of depletion of plasma FXIII-A in the various cre/lox crosses ( Table 2 ) closely resembles that of aortic FXIII-A mRNA, implicating cells identical or related to aortic resident macrophages as the source of plasma FXIII-A. FXIII-A within aortic macrophages has been implicated in arterial repair and remodeling. 19 If local release contributes to this function, this could also suggest that aortic macrophages, or cells similar to them, release FXIII-A into the plasma. Similarly, placental macrophages express FXIII-A and may stabilize this organ during pregnancy. 4 Because intravenous FXIII-A prevents spontaneous abortion, 29 this shows that the requirement is extracellular and suggests that placental macrophages can release FXIII-A.
The hypothesis that resident macrophages release plasma FXIII-A is consistent with the outcomes of most human BMT protocols. [9] [10] [11] In contrast to Wölpl et al, 8 Poon et al 11 observed that conversion from donor to recipient plasma FXIII-A variant occurred over many months after BMT. Further, Inbal et al 9 and Pihusch et al 10 observed that BMT caused a much greater decrease in platelet count than plasma FXIII-A, which led Pihusch et al 10 to suggest that resident macrophages maintain the plasma pool. Notably, alveolar macrophages persist for ≤80 days after BMT. 30, 31 Further, the results of these studies seem inconsistent with release occurring from circulating monocytes, because, like platelets, these cells are short-lived. 32 BMT of FXIII-A pos cells into FXIII-A −/− mice rescued plasma FXIII-A to normal levels, while transfer into FXIII-A +/+ mice caused no further increase in plasma FXIII-A. This may imply that the transplanted cells differentiate within a limited number of niches to become FXIII-A-releasing cells. 33, 34 Recent studies have shown that arterial macrophages arise variously from (1) YS macrophages, (2) fetal liver monocytes, and (3) a short wave of BM monocytes. 35 To determine whether, under normal conditions, monocytes repopulate heart and artery and become FXIII-A-releasing cells, we generated Fms-like tyrosine kinase 3-cre.Flox mice. These recombine in definitive but not primitive hematopoietic cells, 36 that is, BM and some fetal liver cells 37 but not YS-derived cells. The Fms-like tyrosine kinase 3-cre transgene becomes fully active only in a minority of mice. 33, 38 One out of 20 Fms-like tyrosine kinase 3-cre.Flox mice underwent efficient recombination and reduced plasma FXIII-A to 34% ( Figure IV in the online-only Data Supplement). Assuming that this result is representative, it would imply that a proportion of FXIII-A-releasing cells derive from fetal liver or BM-derived cells, presumably monocytes. This would resemble the situation described for arterial macrophages. 35 Our model is shown in Figure 5 : the aorto-gonadmesonephros is an early site of hematopoiesis, 39 and because it is known that vascular macrophages in the early embryo express FXIII-A, 40 it seems probable that they establish here, persist within the developing aorta, and survive postnatally. Monocyte-derived macrophages subsequently supplement, or partially displace, YS-derived macrophages and contribute to plasma FXIIII-A. Although we have shown that aortic macrophages resemble the plasma FXIII-A-releasing cells, resident macrophages in other tissues may contribute. The main limitation of the present study is that we have not directly demonstrated that macrophages release FXIII-A. Previously, we detected nonclassical secretion in vitro of interleukin-1β, but not FXIII-A, from IL-4-treated adherent THP-1 cells, which resemble resident macrophages. 41 In addition, we have detected externalization of the closely related protein transglutaminase 2, 42, 43 but not of FXIII-A, to the surface of mouse macrophages and THP-1 cells ( Figure V in the online-only Data Supplement). It may transpire that FXIII-A is released primarily (1) within tissue niches or (2) from Li6C lo resident macrophage precursors, 44 and that these cells were sparse in culture. Further studies may address these issues by (1) adoptive transfer of defined macrophage precursors, (2) enriching cultures for particular cell types, or (3) establishing coculture models that mimic niches. In conclusion, our studies . Macrophages migrate from the AGM to colonize fetal tissues, including the heart and brain, while some establish in the developing aorta (3). Primitive macrophages persist postnatally. The onset of hematopoiesis within the fetal liver generates monocytes (light blue) that supplement and partially displace YS-derived macrophages (4) . Both populations of resident macrophages can maintain themselves within tissues. The onset of hematopoiesis within the BM (white) generates monocytes (dark blue), which supplement the aortic and heart macrophage population over a short time interval (dotted lines). These cells may also differentiate into resident macrophages (5) . Plasma factor (F)XIII-A is released from cells similar or identical to aortic resident macrophages (6) , and its origin is distinct from platelet FXIII-A (green).
exclude the platelet and all its precursors as the major source of plasma FXIII-A and instead implicate that resident macrophages maintain plasma FXIII-A.
